Rheumatoid arthritis treatment and the risk of severe interstitial lung disease

References

• Wolfe F., Mitchell D. M., Sibley J. T., Fries J. F., Bloch D. A., Williams C. A., et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481–94
   PubMed Web of Science ®Google Scholar
• Dawson J. K., Fewins H. E., Desmond J., Lynch M. P., Graham D. R. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001; 56: 622–7
   PubMed Web of Science ®Google Scholar
• Fewins H. E., McGowan I., Whitehouse G. H., Williams J., Mallya R. High definition computed tomography in rheumatoid arthritis associated pulmonary disease. Br J Rheumatol 1991; 30: 214–16
   PubMedGoogle Scholar
• Gabbay E., Tarala R., Will R., Carroll G., Adler B., Cameron D., et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997; 156((2 Pt 1))528–35
   PubMed Web of Science ®Google Scholar
• Mcdonagh J., Greaves M., Wright A. R., Heycock C., Owen J. P., Kelly C. High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease. Br J Rheumatol 1994; 33: 118–22
   PubMedGoogle Scholar
• Cortet B., Perez T., Roux N., Flipo R. M., Duquesnoy B., Delcambre B., et al. Pulmonary function tests and high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56: 596–600
   PubMed Web of Science ®Google Scholar
• Hubbard R., Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford) 2002; 41: 676–9
   PubMed Web of Science ®Google Scholar
• Hakala M. Poor prognosis in patients with rheumatoid arthritis hospitalized for interstitial lung fibrosis. Chest 1988; 93: 114–18
   PubMed Web of Science ®Google Scholar
• Turner‐Warwick M., Burrows B., Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980; 35: 171–80
   PubMed Web of Science ®Google Scholar
• Soler M. J., Barroso E., Aranda F. I., Alonso S., Romero S. Fatal, gold‐induced pneumonitis. Rheumatol Int 2003; 23: 207–10
   PubMed Web of Science ®Google Scholar
• Evans R. B., Ettensohn D. B., Fawaz Estrup F., Lally E. V., Kaplan S. R. Gold lung: recent developments in pathogenesis, diagnosis, and therapy. Semin Arthritis Rheum 1987; 16: 196–205
   PubMed Web of Science ®Google Scholar
• Scott D. L., Bradby G. V., Aitman T. J., Zaphiropoulos G. C., Hawkins C. F. Relationship of gold and penicillamine therapy to diffuse interstitial lung disease. Ann Rheum Dis 1981; 40: 136–41
   PubMed Web of Science ®Google Scholar
• Kay A. European League against Rheumatism study of adverse reactions to D‐penicillamine. Br J Rheumatol 1986; 25: 193–8
   PubMedGoogle Scholar
• Shettar S. P., Chattopadhyay C., Wolstenholme R. J., Swinson D. R. Diffuse alveolitis on a small dose of penicillamine. Br J Rheumatol 1984; 23: 220–4
   PubMedGoogle Scholar
• Wolfe F., Schurle D. R., Lin J. J., Polland S. M., Smith T. W., Montgomery Short R., et al. Upper and lower airway disease in penicillamine treated patients with rheumatoid arthritis. J Rheumatol 1983; 10: 406–10
   PubMed Web of Science ®Google Scholar
• Ulubas B., Sahin G., Ozer C., Aydin O., Ozgur E., Apaydin D. Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis. Clin Rheumatol 2004; 23: 249–51
   PubMed Web of Science ®Google Scholar
• Hamadeh M. A., Atkinson J., Smith L. J. Sulfasalazine‐induced pulmonary disease. Chest 1992; 101: 1033–7
   PubMed Web of Science ®Google Scholar
• Timmer R., Duurkens V. A. M., Vanhees P. A. M. Sulphasalazine‐induced eosinophilic pneumonia. Neth J Med 1992; 41: 153–7
   PubMed Web of Science ®Google Scholar
• Alarcon G. S., Kremer J. M., Macaluso M., Weinblatt M. E., Cannon G. W., Palmer W. R., et al. Risk factors for methotrexate‐induced lung injury in patients with rheumatoid arthritis – a multicenter, case–control study. Ann Intern Med 1997; 127: 356–64
   PubMed Web of Science ®Google Scholar
• Cannon G. W. Methotrexate pulmonary toxicity. Rheum Dis Clin N Am 1997; 23: 917–37
   PubMed Web of Science ®Google Scholar
• Carroll G. J., Thomas R., Phatouros C. C., Atchison M. H., Leslie A. L., Cook N. J., et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 1994; 21: 51–4
   PubMed Web of Science ®Google Scholar
• Rosenow E. C III. Drug‐induced pulmonary disease. Dis Mon 1994; 40: 253–310
   PubMed Web of Science ®Google Scholar
• Leduc D., De Vuyst P., Lheureux P., Gevenois P. A., Jacobovitz D., Yernault J. C. Pneumonitis complicating low‐dose methotrexate therapy for rheumatoid arthritis. Discrepancies between lung biopsy and bronchoalveolar lavage findings. Chest 1993; 104: 1620–3
   PubMed Web of Science ®Google Scholar
• Green L., Schattner A., Berkenstadt H. Severe reversible interstitial pneumonitis induced by low dose methotrexate: report of a case and review of the literature[see comments]. J Rheumatol 1988; 15: 110–12
   PubMed Web of Science ®Google Scholar
• Cannon G. W., Ward J. R., Clegg D. O., Samuelson C. O Jr., Abbott T. M. Acute lung disease associated with low‐dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthritis Rheum 1983; 26: 1269–74
   PubMed Web of Science ®Google Scholar
• Kramer N., Chuzhin Y., Kaufman L. D., Ritter J. M., Rosenstein E. D. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 2002; 47: 670–1
   PubMed Web of Science ®Google Scholar
• Chatterjee S. Severe interstitial pneumonitis associated with infliximab therapy. Scand J Rheumatol 2004; 33: 276–7
   PubMed Web of Science ®Google Scholar
• McCurry J. Japan deaths spark concerns over arthritis drug. Lancet 2004; 363: 461
   PubMed Web of Science ®Google Scholar
• Scott D. L. Interstitial lung disease and disease modifying anti‐rheumatic drugs. Lancet 2004; 363: 1239–40
   PubMed Web of Science ®Google Scholar
• Courtney P. A., Alderdice J., Whitehead E. M. Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 2003; 49: 617–18
   PubMed Web of Science ®Google Scholar
• Ostor A. J., Chilvers E. R., Somerville M. F., Lim A. Y., Lane S. E., Crisp A. J., et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 2006; 33: 622–8
   PubMed Web of Science ®Google Scholar
• Wolfe F., Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti‐tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740–51
   PubMed Web of Science ®Google Scholar
• Wolfe F., Michaud K., Anderson J., Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372–9
   PubMed Web of Science ®Google Scholar
• Wolfe F., Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti‐tumor necrosis factor therapy. Am J Med 2004; 116: 305–11
   PubMed Web of Science ®Google Scholar
• Michaud K., Messer J., Choi H. K., Wolfe F. Direct medical costs and their predictors in persons with rheumatoid arthritis: a 3 year study of 7,527 patients. Arthritis Rheum 2003; 48: 2750–62
   PubMed Web of Science ®Google Scholar
• Fries J. F., Spitz P. W., Young D. Y. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9: 789–93
   PubMed Web of Science ®Google Scholar
• Fries J. F., Spitz P. W., Kraines R. G., Holman H. R. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137–45
   PubMed Web of Science ®Google Scholar
• Ware J. E. J., Kosinski M. The SF‐36® physical and mental health summary scales: a manual for users of version 1, second edition. QualityMetric, Lincoln, RI 2001
   Google Scholar
• Ware J. E., Sherbourne C. D. The MOS 36‐item short‐form health survey (SF‐36). 1. Conceptual framework and item selection. Med Care 1992; 30: 473–83
   PubMed Web of Science ®Google Scholar
• Doody M. M., Hayes H. M., Bilgrad R. Comparability of National Death Index Plus and standard procedures for determining causes of death in epidemiologic studies. Ann Epidemiol 2001; 11: 46–50
   PubMed Web of Science ®Google Scholar
• Edlavitch S. A., Baxter J. Comparability of mortality follow‐up before and after the National Death Index. Am J Epidemiol 1988; 127: 1164–78
   PubMed Web of Science ®Google Scholar
• Stata Statistical Software: Release 8.2. College Station, TX: Stata Corporation, 2003
   Google Scholar
• Ellman P., Ball R. E. Rheumatoid disease with joint and pulmonary manifestations. Br Med J 1948; 2: 816–20
   PubMed Web of Science ®Google Scholar
• Provenzano G., Pardo V., Danato G. [Asymptomatic pulmonary involvement in rheumatoid arthritis] Italian. Rassegna di Patologia dell'Apparato Respiratorio 2003; 18: 279–82
   Google Scholar
• Saravanan V., Kelly C. A. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 143–7
   PubMed Web of Science ®Google Scholar
• Committee on Safety of Medicines, Methotrexate and pneumonitis. 5. 2003. Medicines and Healthcare products Regulatory Agency
   Google Scholar
• Kremer J. M., Cannon G. W. Benefit/risk of leflunomide in rheumatoid arthritis. Clin Exp Rheumatol 2004; 22((5 Suppl 35))S95–100
   Google Scholar
• Saag K. G., Kolluri S., Koehnke R. K., Georgou T. A., Rachow J. W., Hunninghake G. W., et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum 1996; 39: 1711–19
   PubMed Web of Science ®Google Scholar
• Dawson J. K., Graham D. R., Desmond J., Fewins H. E., Lynch M. P. Investigation of the chronic pulmonary effects of low‐dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) 2002; 41: 262–7
   PubMed Web of Science ®Google Scholar
• Dayton C. S., Schwartz D. A., Sprince N. L., Yagla S. J., Davis C. S., Koehnke R. K., et al. Low‐dose methotrexate may cause air trapping in patients with rheumatoid arthritis. Am J Respir Crit Care Med 1995; 151: 1189–93
   PubMed Web of Science ®Google Scholar
• Camiciottoli G., Trapani S., Castellani W., Ginanni R., Ermini M., Falcini F. Effect on lung function of methotrexate and non‐steroid anti‐inflammatory drugs in children with juvenile rheumatoid arthritis. Rheumatol Int 1998; 18: 11–16
   PubMed Web of Science ®Google Scholar
• Suissa S., Hudson M., Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006; 54: 1435–9
   PubMed Web of Science ®Google Scholar
• Kremer J. M., Alarcon G. S., Weinblatt M. E., Kaymakcian M. V., Macaluso M., Cannon G. W., et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate‐associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997; 40: 1829–37
   PubMed Web of Science ®Google Scholar
• Keser G., Capar I., Aksu K., Inal V., Danaoglu Z., Savas R., et al. Pulmonary hypertension in rheumatoid arthritis. Scand J Rheumatol 2004; 33: 244–5
   PubMed Web of Science ®Google Scholar
• Turesson C., Jacobsson L. T. Epidemiology of extra‐articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2004; 33: 65–72
   PubMed Web of Science ®Google Scholar
• Cannon G., Strand V., Simon L. S., Kavanaugh A. F., Hochberg M. C., Scarazinni L., et al. Interstitial lung disease in rheumatoid arthritis patients receiving leflunomide. Arthritis RheumSuppl) 2004; 50: S561
   Google Scholar
• Smolen J. S., Emery P. Efficacy and safety of leflunomide in active rheumatoid arthritis. Rheumatology (Oxford) 2000; 39((Suppl 1))48–56
   PubMed Web of Science ®Google Scholar